Bioenergy Rides Pharma Science Down Rx, Supplement Roads
This article was originally published in The Pink Sheet Daily
Executive Summary
Bioenergy Life Science, a subsidiary of biotech firm Bioenergy, is designing phase III clinical studies and plans to submit an NDA for Bioenergy Ribose in parenteral form for acute use in pre- and post-surgical patients and as a biologic preservative.
You may also be interested in...
Petitioning FDA Is "Hard" But "Right Way" To Sell Former IND As Supplement
A recent citizen petition blazes a trail for companies to market ingredients for supplements that would otherwise be regulated as drugs after previously undergoing investigation as a drug
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.